NasdaqCM - Nasdaq Real Time Price USD

Aditxt, Inc. (ADTX)

2.3900

-0.1400

(-5.53%)

At close: 4:00 PM EDT

2.3800

-0.01

(-0.42%)

After hours: 5:41 PM EDT

Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)

MOUNTAIN VIEW, Calif., April 02, 2024--Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, today announced that it has entered into a definitive arrangement agreement ("Arrangement Agreement") to acquire Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) ("Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. Under the Arrangement Agree

Business Wire 24 days ago

APLIF

ADTX
-5.53%
Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023

The company behind Phexxi® (lactic acid, citric acid, and potassium bitartrate) vaginal gel, women's health innovator Evofem Biosciences, Inc. (OTCQB: EVFM), today announced financial results for the fourth quarter and year ended December 31, 2023. Highlights include:

PR Newswire 30 days ago

EVFM

ADTX
-5.53%
For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy

Use of GLP-1 receptor agonists, or GLP-1s, is skyrocketing in the United States, with more than nine million prescriptions for Ozempic, Wegovy, Mounjaro, and similar diabetes and obesity drugs written during the last three months of 2022 alone.1 Zepbound weekly prescriptions hit 25,000 in December 2023, just one month after it was approved to treat obesity.2 These drugs may make oral birth control pills less effective at certain points in the dosing schedule, making an unintended pregnancy more

PR Newswire last month

EVFM

ADTX
-5.53%
Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023

Evofem Biosciences, Inc. (OTCQB: EVFM) today announced strong preliminary, unaudited results for fiscal 2023, including record net sales of Phexxi® (lactic acid, citric acid, and potassium bitartrate), its hormone-free contraceptive gel, and the Company's lowest total operating expenses since becoming a commercial stage company in 2020.

PR Newswire 2 months ago

ADTX
-5.53%
EVFM
Aditxt, Inc. Acquires Proprietary Electroencephalography (EEG) Brain Monitoring Technologies and Devices, Including NeuroCap™ and NeuroEEG™ for Telehealth and Tele-neurology Applications

RICHMOND, Va., January 30, 2024--Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, today announced the acquisition of a portfolio of EEG brain monitoring technologies and devices formerly owned by Brain Scientific, Inc. ("Brain Scientific"). The products targeting the neurology monitoring market will be essential in shaping its dynamic landscape for neurological care.

Business Wire 2 months ago

ADTX
-5.53%
Aditxt, Inc.’s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.’s Proprietary Mitomic™ Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 Million

RICHMOND, Va., January 08, 2024--Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, today announces that the Company and its subsidiary, Pearsanta, Inc. ("Pearsanta"), has acquired MDNA Life Sciences Inc.’s ("MDNA") proprietary, early disease and cancer detection platform. This strategic move reinforces Pearsanta’s dedication to enhancing patient outcomes through early disease detection and the powe

Business Wire 3 months ago

ADTX
-5.53%
Aditxt Announces Closing of $6.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

RICHMOND, Va., January 05, 2024--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has closed its previously announced private placement for the purchase and sale of an aggregate of 1,237,114 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $4.85 per share (or pre-funded warrants in lieu thereof) and ac

Business Wire 3 months ago

ADTX
-5.53%
Aditxt, Inc. Regains Compliance with Nasdaq Stockholders’ Equity Requirement

RICHMOND, Va., January 02, 2024--Aditxt, Inc. ("Aditxt" or "the Company") (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, today announced that it has received confirmation from The Nasdaq Stock Market LLC ("Nasdaq") Hearing Panel that it has regained compliance with minimum stockholders’ equity requirement in Nasdaq Listing Rule 5550(b)(1), subject to a mandatory panel monitor until December 29, 2024.

Business Wire 3 months ago

ADTX
-5.53%
Aditxt Announces $6 Million Private Placement Priced At-The-Market under Nasdaq Rules

RICHMOND, Va., December 29, 2023--Aditxt, Inc., (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,237,114 shares of common stock (or pre-funded warrant in lieu thereof) at a purchase price of $4.85 per share (or pre-funded warrant in lieu thereof) and accompanying warr

Business Wire 3 months ago

ADTX
-5.53%
Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi®, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive Health Needs of Women Globally

RICHMOND, Va. & SAN DIEGO, December 12, 2023--Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, and Evofem Biosciences, Inc. ("Evofem") (OTCQB: EVFM), a pioneer in women’s health, today announced the signing of a definitive agreement (the "Agreement") under which Aditxt is to acquire Evofem in consideration of the issuance of a combination of common stock and preferred stock, and the assumption of

Business Wire 4 months ago

EVFM

ADTX
-5.53%
Aditxt, Inc. to Present at 8th Annual Dawson James Conference

Chief Executive Officer, Amro Albanna to Present at 9:00am Eastern Time on Thursday, October 12, 2023Richmond, VA, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt” or the "Company"), an innovation activation company focused on the discovery, development, and deployment of technologies that monitor and modulate the immune system will present at the 8th Annual Dawson James Conference on Thursday, October 12, 2023, at the Wyndam Grand Jupiter at Harbourside Place in Jupiter,

GlobeNewswire 6 months ago

ADTX
-5.53%
Aditxt, Inc. Announces Appointment of Ernie Lee as CEO of its Wholly-Owned Subsidiary, Pearsanta, to Lead Launch of Test2Treat.me Platform

MOUNTAIN VIEW, Calif., October 05, 2023--Aditxt, Inc., (NASDAQ: ADTX) ("Aditxt" or the "Company"), a global innovation activation company focused on the discovery, development, and deployment of technologies that monitor and modulate the immune system, announced today that it has appointed Ernie Lee to serve as the Chief Executive Officer of the Company’s wholly-owned subsidiary Pearsanta, Inc. ("Pearsanta"). Ernie’s appointment is intended to accelerate the commercial launch of Test2Treat.me. T

Business Wire 6 months ago

ADTX
-5.53%
Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference

JUPITER, Fla., Sept. 21, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- Dawson James Securities, Inc. (“Dawson”), a full-service investment bank focused on emerging growth companies, today announces its 8th Annual Dawson James Small Cap Growth Conference on October 12, 2023, at the Wyndham Grand Hotel in Jupiter, FL. Dawson James’ flagship Small Cap Growth Conference brings together senior leadership from over 30 of the most innovative companies at the forefront of healthcare, technology and consu

GlobeNewswire 7 months ago

BITF

ANVS

MTNB
Aditxt, Inc. (NASDAQ: ADTX) Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference September 11th-13th, 2023

RICHMOND, Va. & MOUNTAIN VIEW, Calif., September 08, 2023--Aditxt,® Inc, (NASDAQ: ADTX) ("Aditxt" or the "Company"), a global innovation company focused on developing and commercializing technologies that monitor and modulate the immune system, today announced that the Aditxt management team will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11th -13th, 2023, in New York City. The in-person venue for the event is the Lotte New York Palace Hotel

Business Wire 7 months ago

ADTX
-5.53%
Aditxt Announces Closing of $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

RICHMOND, Va., September 06, 2023--Aditxt, Inc., (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has closed its previously announced private placement for the purchase and sale of an aggregate of 1,000,000 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $10.00 per share (or pre-funded warrants in lieu thereof) an

Business Wire 7 months ago

ADTX
-5.53%
Aditxt Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

RICHMOND, Va., August 31, 2023--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,000,000 shares of common stock (or pre-funded warrant in lieu thereof) at a purchase price of $10.00 per share (or pre-funded warrant in lieu thereof) and accompanying warran

Business Wire 7 months ago

ADTX
-5.53%
Aditxt, Inc. (NASDAQ: ADTX) Provides Shareholder Update and Planned Strategy for Achieving Commercial Scale

RICHMOND, Va., August 18, 2023--Aditxt®, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a global innovation company focused on innovation and activation of precision medicine therapeutics and technologies that monitor and modulate the immune system, is pleased to provide an important update regarding its innovation programs and strategic M&A initiatives.

Business Wire 8 months ago

ADTX
-5.53%
CORRECTING and REPLACING Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on August 18, 2023

RICHMOND, Va., August 17, 2023--First paragraph, first sentence of release should read: Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt or the "Company"), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, announced today that it will effect a 1-for-40 reverse split of its common stock (instead of Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt or the "Company"), a global innovation company focused on therapeutics and technologies that monitor and modulat

Business Wire 8 months ago

ADTX
-5.53%
Aditxt, Inc.’s Wholly-Owned Subsidiary Pearsanta, Inc. Looks to Expand Customer Base, Payor Access, and Genetic Testing with a Non-Binding Letter of Intent to Acquire Natural State Laboratories and Natural State Genomics

RICHMOND, Va., June 20, 2023--Aditxt,® Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, is pleased to announce the signing of an exclusive non-binding Letter of Intent ("LOI") by Pearsanta,™ Inc. ("Pearsanta"), a wholly-owned subsidiary of Aditxt, to acquire both Natural State Laboratories, LLC ("NSL") and Natural State Genomics, LLC ("NSG") (collectively, "Natural State Entities" or

Business Wire 10 months ago

ADTX
-5.53%
Aditxt First Quarter 2023 Earnings: US$1.31 loss per share (vs US$6.80 loss in 1Q 2022)

Aditxt ( NASDAQ:ADTX ) First Quarter 2023 Results Key Financial Results Revenue: US$218.4k (up 3.9% from 1Q 2022). Net...

Simply Wall St. 11 months ago

ADTX
-5.53%

Performance Overview

Return	ADTX	S&P 500
YTD	-63.95%	+6.92%
1-Year	-91.40%	+25.26%
3-Year	-99.95%	+22.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Aditxt, Inc. (ADTX)

Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)

Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023

For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy

Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023

Aditxt, Inc. Acquires Proprietary Electroencephalography (EEG) Brain Monitoring Technologies and Devices, Including NeuroCap™ and NeuroEEG™ for Telehealth and Tele-neurology Applications

Aditxt, Inc.’s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.’s Proprietary Mitomic™ Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 Million

Aditxt Announces Closing of $6.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

Aditxt, Inc. Regains Compliance with Nasdaq Stockholders’ Equity Requirement

Aditxt Announces $6 Million Private Placement Priced At-The-Market under Nasdaq Rules

Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi®, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive Health Needs of Women Globally

Aditxt, Inc. to Present at 8th Annual Dawson James Conference

Aditxt, Inc. Announces Appointment of Ernie Lee as CEO of its Wholly-Owned Subsidiary, Pearsanta, to Lead Launch of Test2Treat.me Platform

Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference

Aditxt, Inc. (NASDAQ: ADTX) Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference September 11th-13th, 2023

Aditxt Announces Closing of $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

Aditxt Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

Aditxt, Inc. (NASDAQ: ADTX) Provides Shareholder Update and Planned Strategy for Achieving Commercial Scale

CORRECTING and REPLACING Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on August 18, 2023

Aditxt, Inc.’s Wholly-Owned Subsidiary Pearsanta, Inc. Looks to Expand Customer Base, Payor Access, and Genetic Testing with a Non-Binding Letter of Intent to Acquire Natural State Laboratories and Natural State Genomics

Aditxt First Quarter 2023 Earnings: US$1.31 loss per share (vs US$6.80 loss in 1Q 2022)

Performance Overview